Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H30N4O3.C4H4O4 |
| Molecular Weight | 538.5922 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CNC(=O)C1=CC=C2[C@H](CCN3CCN(CC3)C4=CC=C(C=C4)C(N)=O)OCCC2=C1
InChI
InChIKey=GYOIZJALBHBRIJ-PCBAQXHCSA-N
InChI=1S/C24H30N4O3.C4H4O4/c1-26-24(30)19-4-7-21-18(16-19)9-15-31-22(21)8-10-27-11-13-28(14-12-27)20-5-2-17(3-6-20)23(25)29;5-3(6)1-2-4(7)8/h2-7,16,22H,8-15H2,1H3,(H2,25,29)(H,26,30);1-2H,(H,5,6)(H,7,8)/b;2-1-/t22-;/m0./s1
| Molecular Formula | C24H30N4O3 |
| Molecular Weight | 422.52 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11595000
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11595000
PNU-142633 is selective 5HT1D partial agonist, developed by Pharmacia & Upjohn, Inc. It failed in phase II clinical trials against acute migraine, and its development was discontinued.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10385247
Curator's Comment: Pharmacia was obtained by Pfizer.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14643336 |
4.6 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
141 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11595000 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PNU-142633 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11595000
In phase II clinical trials patients received a single 50-mg oral dose of a 5-HT(1D) agonist, PNU-142633 during an acute migraine attack.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10385247
Receptor binding studies were performed on 5HT1D receptors, expressed in HEK293 cells. Binding of [3H]-serotonin was measured in membranes, using filtration techniques.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:08:32 GMT 2025
by
admin
on
Mon Mar 31 18:08:32 GMT 2025
|
| Record UNII |
VF98F3655P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
VF98F3655P
Created by
admin on Mon Mar 31 18:08:32 GMT 2025 , Edited by admin on Mon Mar 31 18:08:32 GMT 2025
|
PRIMARY | |||
|
249765-69-3
Created by
admin on Mon Mar 31 18:08:32 GMT 2025 , Edited by admin on Mon Mar 31 18:08:32 GMT 2025
|
PRIMARY | |||
|
10052962
Created by
admin on Mon Mar 31 18:08:32 GMT 2025 , Edited by admin on Mon Mar 31 18:08:32 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |